Skip to main content

Inari Medical Prospective Clinical Data on the FlowTriever System to be Presented in Late-Breaking Session at TCT Connect

Written by Customer Service on . Posted in Public Companies.

IRVINE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever System for treatment of pulmonary embolism (PE) in a real-world patient population. Interim data on the first 230 patients enrolled at 19 US sites will be presented in the late-breaking session.
“We are excited to feature the interim FLASH data as part of a late-breaking session at TCT Connect,” said Thomas Tu, MD, Chief Medical Officer of Inari Medical. “FLASH will help advance the understanding and treatment of PE, and I would like to thank all of the investigators, research coordinators, and patients who have supported this important work. We look forward to the interim results being shared at TCT Connect.”The details of the late-breaking session are as follows:Following the late-breaker presentation, on Sunday, October 18, at 3pm ET, Inari Medical is hosting a TCT Connect E-Training Session. The pre-recorded webinar will include remarks from Dr. Catalin Toma on the interim FLASH results as well as a discussion with a panel of experts.About FLASH
FLASH is a 500-patient prospective, multicenter, single-arm registry evaluating the safety and effectiveness of the FlowTriever System for treatment of PE in a real-world patient population. The study is assessing freedom from major adverse events within 48 hours of the index procedure as the primary endpoint. Secondary endpoints include impact on acute hemodynamics, procedural measures, 48h all-cause mortality, and longer-term patient outcomes. The national principal investigator of the study is Catalin Toma, MD, Director of Interventional Cardiology at UPMC Heart and Vascular Institute in Pittsburgh, PA.About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.